



# Coding-Complete Genome Sequences of Six Influenza Type A Strains Circulating in Lithuania in the 2009–2010 Epidemic Season

 Lukasz Rabalski,<sup>a</sup> Boguslaw Szewczyk,<sup>a</sup> Kęstutis Zagminas,<sup>b</sup> Algirdas Griskevicius,<sup>c</sup>  Krzysztof Lepek<sup>a</sup>

<sup>a</sup>Laboratory of Recombinant Vaccines, Intercollegiate Faculty of Biotechnology, University of Gdansk and Medical University of Gdansk, Gdansk, Poland

<sup>b</sup>Vilnius University, Faculty of Medicine, Public Health Institute, Vilnius, Lithuania

<sup>c</sup>National Public Health Surveillance Laboratory, Vilnius, Lithuania

**ABSTRACT** Here, we report the coding-complete genome sequences of six influenza A (H1N1) strains that were detected in Vilnius, Lithuania, among patients exhibiting influenza-like symptoms during the 2009–2010 epidemic season, within national influenza surveillance. Several mutations were found in genes encoding hemagglutinin and neuraminidase, in comparison with the A/California/07/2009 reference strain (GenBank accession numbers [NC\\_026433](#) and [NC\\_026434](#)).

**B**elonging to the family *Orthomyxoviridae*, genus *Alphainfluenzavirus*, the influenza type A virus causes annual human and animal influenza. The manifestation of the disease may take the form of seasonal waves of cases, local epidemics, or global pandemics caused by the emergence of antigenically different strains (1).

Lack of immunity to such strains in the human population is caused by continuous genetic variation of the virus, which is based on phenomena such as reassortment (exchange of genetic segments between two different viruses), antigenic shift (changes of genetic segments encoding the major surface antigens), and antigenic drift (slow accumulation of small variations in sequences encoding the major surface antigens) (2, 3). Therefore, it is important to not only keep tracking the current genetic diversity of these viruses but also take a look at changes that occurred in the past to have a full set of data for accurate estimation of the antigenic drift and what course it may take (4, 5).

Viral RNA was isolated, using the RNeasy purification kit (Qiagen), from oropharyngeal swabs collected by the National Public Health Surveillance Laboratory of Lithuania during the 2009–2010 epidemic season from patients showing influenza symptoms such as fever, coughing, headache, and chills. The Vilnius Regional Bioethics Committee approved the study protocol; this was deemed minimal risk, and the requirement for written consent was waived. The samples were positively diagnosed as A(H1N1) with a reverse transcription-quantitative PCR (RT-qPCR) assay using primers and probes recommended by the World Health Organization (6, 7). For all A(H1N1) genomic segments, reverse transcription and PCR amplification were performed using PathAmp FluA reagents (8). Postreaction cleanup was done on Agencourt AMPure XP magnetic beads (Beckman Coulter). We performed full genome sequencing on the MiSeq platform (Illumina) with v3 sequencing chemistry. For genomic library preparation, a Nextera XT DNA sample preparation kit (Illumina) was used. Paired-end reads of the target size  $2 \times 300$  bp were generated (isolate 1167, 2,514,242 reads; isolate 1172, 1,185,476 reads; isolate 1241, 1,758,300 reads; isolate 1305, 1,675,062 reads; isolate 1319, 2,687,104 reads; isolate 1324, 1,299,004 reads). Data were gathered as fastq files and further analyzed with Geneious Prime v20.2 software (Biomatters) using integrated tools (trimming, i.e., deleting 3' and 5' ends with an error probability limit of 0.05) and the BBNorm package v38.84 (<https://sourceforge.net/projects/bbmap>) (error correction

**Citation** Rabalski L, Szewczyk B, Zagminas K, Griskevicius A, Lepek K. 2021. Coding-complete genome sequences of six influenza type A strains circulating in Lithuania in the 2009–2010 epidemic season. *Microbiol Resour Announc* 10:e01274-20. <https://doi.org/10.1128/MRA.01274-20>.

**Editor** John J. Dennehy, Queens College

**Copyright** © 2021 Rabalski et al. This is an open-access article distributed under the terms of the [Creative Commons Attribution 4.0 International license](#).

Address correspondence to Krzysztof Lepek, [krzysztof.lepek@biotech.u.gdansk.pl](mailto:krzysztof.lepek@biotech.u.gdansk.pl).

**Received** 10 November 2020

**Accepted** 30 November 2020

**Published** 7 January 2021

**TABLE 1** Accession numbers and characteristics of influenza A(H1N1) isolates deposited in GenBank

Isolate	Segment	Segment size (bp)	Similarity to reference (%) <sup>a</sup>	G+C content (%)	Accession no.
1167	PB2	2,280	99.65	44.6	<a href="#">MW185783</a>
	PB1	2,274	99.91	42.0	<a href="#">MW185784</a>
	PA	2,151	99.70	44.1	<a href="#">MW185785</a>
	HA	1,701	99.53	40.6	<a href="#">MW185786</a>
	NP	1,497	99.70	46.0	<a href="#">MW185787</a>
	NA	1,410	99.65	42.1	<a href="#">MW185788</a>
	M	982	99.69	47.1	<a href="#">MW185789</a>
	NS	863	99.65	43.7	<a href="#">MW185790</a>
1172	PB2	2,280	99.74	44.7	<a href="#">MW185791</a>
	PB1	2,274	99.96	42.0	<a href="#">MW185792</a>
	PA	2,151	99.56	44.1	<a href="#">MW185793</a>
	HA	1,701	99.59	40.7	<a href="#">MW185794</a>
	NP	1,497	99.43	45.8	<a href="#">MW185795</a>
	NA	1,410	99.57	42.0	<a href="#">MW185796</a>
	M	982	99.69	47.0	<a href="#">MW185797</a>
	NS	863	99.54	43.8	<a href="#">MW185798</a>
1241	PB2	2,280	99.65	44.6	<a href="#">MW185828</a>
	PB1	2,274	99.60	42.2	<a href="#">MW185829</a>
	PA	2,151	99.74	44.2	<a href="#">MW185830</a>
	HA	1,701	99.59	40.7	<a href="#">MW185831</a>
	NP	1,497	99.30	45.9	<a href="#">MW185832</a>
	NA	1,410	99.65	42.1	<a href="#">MW185833</a>
	M	982	99.80	46.9	<a href="#">MW185834</a>
	NS	863	99.77	43.8	<a href="#">MW185835</a>
1305	PB2	2,280	99.61	44.7	<a href="#">MW185803</a>
	PB1	2,274	99.60	42.3	<a href="#">MW185806</a>
	PA	2,151	99.70	44.1	<a href="#">MW185804</a>
	HA	1,701	99.41	40.5	<a href="#">MW185800</a>
	NP	1,497	99.37	46.0	<a href="#">MW185805</a>
	NA	1,410	99.65	42.1	<a href="#">MW185799</a>
	M	982	99.80	46.9	<a href="#">MW185802</a>
	NS	863	99.88	43.7	<a href="#">MW185801</a>
1319	PB2	2,280	99.65	44.7	<a href="#">MW185811</a>
	PB1	2,274	99.60	42.2	<a href="#">MW185814</a>
	PA	2,151	99.74	44.2	<a href="#">MW185812</a>
	HA	1,701	99.47	40.6	<a href="#">MW185808</a>
	NP	1,497	99.37	46.0	<a href="#">MW185813</a>
	NA	1,410	99.65	42.1	<a href="#">MW185807</a>
	M	982	99.80	46.9	<a href="#">MW185810</a>
	NS	863	99.88	43.7	<a href="#">MW185809</a>
1324	PB2	2,280	99.65	44.6	<a href="#">MW185819</a>
	PB1	2,274	99.60	42.2	<a href="#">MW185822</a>
	PA	2,151	99.74	44.2	<a href="#">MW185820</a>
	HA	1,701	99.47	40.6	<a href="#">MW185816</a>
	NP	1,497	99.37	46.0	<a href="#">MW185821</a>
	NA	1,410	99.65	42.1	<a href="#">MW185815</a>
	M	982	99.80	46.9	<a href="#">MW185818</a>
	NS	863	99.88	43.7	<a href="#">MW185817</a>

<sup>a</sup> Similarity to reference strain A/California/07/2009 (M segment, GenBank accession number [NC\\_026431](#); NS segment, [NC\\_026432](#); HA segment, [NC\\_026433](#); NA segment, [NC\\_026434](#); PB1 segment, [NC\\_026435](#); NP segment, [NC\\_026436](#); PA segment, [NC\\_026437](#); PB2 segment, [NC\\_026438](#)).

and normalization, i.e., correcting substitution errors based on quality, discarding reads that have a probable coverage of  $2\times$  or less, and reducing the number of reads that have a probable coverage of  $40\times$  or more). *De novo* assembly of contigs was performed using a medium sensitivity script. Final contigs were trimmed to the size of the reference genome (GenBank accession numbers are provided in the footnote of Table 1).

All sequences were aligned, using MAFFT v7.388, against the A/California/07/2009 reference strain circulating among people at that time (9–12). We observed a high degree of similarity ( $>99\%$ ) among all six strains as well as the reference strain (similarity levels are presented in Table 1). These analyses revealed several single-nucleotide polymorphisms that alter the amino acid sequences in two major surface glycoproteins, namely, hemagglutinin (HA) and neuraminidase (NA), i.e., V24I (isolate 1305), R45K (isolates 1319 and 1324), V47G (isolates 1319 and 1324), S74N (isolate 1167), P83S (all isolates), S203T (all isolates), A215V (isolate 1305), I321V (isolates 1167, 1172, 1241, and 1305), I321F (isolates 1319 and 1324), and E374K (all isolates except isolate 1167) in HA and G41V (isolate 1172), I46T (isolate 1167), V106I (all isolates), and N248D (all isolates) in NA. The S74N, P83S, S203T, and A215V substitutions are localized in epitope regions of HA or the immediate vicinity (13). The V47G and S74N substitutions were characterized earlier in our findings, in A(H1N1) isolates collected in Taiwan in 2010 to 2011 (14). None of the isolates harbored the NA drug resistance mutations in the NA gene (15).

**Data availability.** The coding-complete genome sequences of influenza A(H1N1) strains isolated in Vilnius, Lithuania, in 2009 were deposited in GenBank under the accession numbers listed in Table 1. The raw sequencing reads were deposited in the NCBI Sequence Read Archive (SRA) under the accession numbers [SRR13000260](https://www.ncbi.nlm.nih.gov/sra/SRR13000260), [SRR13000261](https://www.ncbi.nlm.nih.gov/sra/SRR13000261), [SRR13000262](https://www.ncbi.nlm.nih.gov/sra/SRR13000262), [SRR13000263](https://www.ncbi.nlm.nih.gov/sra/SRR13000263), [SRR13000264](https://www.ncbi.nlm.nih.gov/sra/SRR13000264), and [SRR13000265](https://www.ncbi.nlm.nih.gov/sra/SRR13000265) and the BioProject accession number [PRJNA675103](https://www.ncbi.nlm.nih.gov/bioproject/PRJNA675103).

## ACKNOWLEDGMENT

This research was conducted with the financial support of the Narodowe Centrum Nauki, Poland (grant 2016/21/D/NZ7/02721).

## REFERENCES

1. Yoon S-W, Webby RJ, Webster RG. 2014. Evolution and ecology of influenza A viruses, p 359–375. In Compans RW, Oldstone MBA (ed), *Influenza pathogenesis and control: volume I*. Springer International Publishing, Cham, Switzerland.
2. Bloom JD, Gong LI, Baltimore D. 2010. Permissive secondary mutations enable the evolution of influenza oseltamivir resistance. *Science* 328:1272–1275. <https://doi.org/10.1126/science.1187816>.
3. Mostafa A, Abdelwhab EM, Mettenleiter TC, Pleschka S. 2018. Zoonotic potential of influenza A viruses: a comprehensive overview. *Viruses* 10:497. <https://doi.org/10.3390/v10090497>.
4. Shao W, Li X, Goraya MU, Wang S, Chen J-L. 2017. Evolution of influenza A virus by mutation and re-assortment. *Int J Mol Sci* 18:1650. <https://doi.org/10.3390/ijms18081650>.
5. Taubenberger JK, Kash JC. 2010. Influenza virus evolution, host adaptation, and pandemic formation. *Cell Host Microbe* 7:440–451. <https://doi.org/10.1016/j.chom.2010.05.009>.
6. Ambrozaitis A, Radzišauskienė D, Žagminas K, Kuprevičienė N, Gravenstein S, Jančorienė L. 2016. Influenza A(H1N1)pdm09 and postpandemic influenza in Lithuania. *Open Med (Wars)* 11:341–353. <https://doi.org/10.1515/med-2016-0064>.
7. World Health Organization. 2009. CDC protocol of realtime RTPCR for influenza A(H1N1). World Health Organization, Geneva, Switzerland. [https://www.who.int/csr/resources/publications/swineflu/CDCRealtimeRTPCR\\_SwineH1Assay-2009\\_20090430.pdf?ua=1](https://www.who.int/csr/resources/publications/swineflu/CDCRealtimeRTPCR_SwineH1Assay-2009_20090430.pdf?ua=1).
8. Applied Biosystems. 2016. PathAmp FluA reagents user guide. Thermo Fisher Scientific, Waltham, MA. [http://tools.thermofisher.com/content/sfs/manuals/MAN0009977\\_PathAmpFluA\\_UG.pdf](http://tools.thermofisher.com/content/sfs/manuals/MAN0009977_PathAmpFluA_UG.pdf).
9. Feshchenko E, Rhodes DG, Felberbaum R, McPherson C, Riningger JA, Post P, Cox MM. 2012. Pandemic influenza vaccine: characterization of A/California/07/2009 (H1N1) recombinant hemagglutinin protein and insights into H1N1 antigen stability. *BMC Biotechnol* 12:77. <https://doi.org/10.1186/1472-6750-12-77>.
10. Laassri M, Majid L, Zagorodnyaya T, Plant EP, Petrovskaya S, Bidzhieva B, Ye Z, Simonyan V, Chumakov K. 2015. Deep sequencing for evaluation of genetic stability of influenza A/California/07/2009 (H1N1) vaccine viruses. *PLoS One* 10:e0138650. <https://doi.org/10.1371/journal.pone.0138650>.
11. Katoh K, Standley DM. 2013. MAFFT multiple sequence alignment software version 7: improvements in performance and usability. *Mol Biol Evol* 30:772–780. <https://doi.org/10.1093/molbev/mst010>.
12. Katoh K, Misawa K, Kuma K, Miyata T. 2002. MAFFT: a novel method for rapid multiple sequence alignment based on fast Fourier transform. *Nucleic Acids Res* 30:3059–3066. <https://doi.org/10.1093/nar/gkf436>.
13. Matsuzaki Y, Sugawara K, Nakauchi M, Takahashi Y, Onodera T, Tsunetsugu-Yokota Y, Matsumura T, Ato M, Kobayashi K, Shimotai Y, Mizuta K, Hongo S, Tashiro M, Nobusawa E. 2014. Epitope mapping of the hemagglutinin molecule of A(H1N1)pdm09 influenza virus by using monoclonal antibody escape mutants. *J Virol* 88:12364–12373. <https://doi.org/10.1128/JVI.01381-14>.
14. Łeppek K, Pająk B, Siedlecki P, Niemcewicz M, Kocik J, Wu H-S, Yang J-R, Kucharczyk K, Szewczyk B. 2014. Genetic diversity of hemagglutinin gene of A(H1N1)pdm09 influenza strains isolated in Taiwan and its potential impact on HA-neutralizing epitope interaction. *Hum Vaccin Immunother* 10:577–585. <https://doi.org/10.4161/hv.27603>.
15. Pokorná J, Páchl P, Karlukova E, Hejdánek J, Rezáčová P, Machara A, Hudlický J, Konvalinka J, Kožíšek M. 2018. Kinetic, thermodynamic, and structural analysis of drug resistance mutations in neuraminidase from the 2009 pandemic influenza virus. *Viruses* 10:339. <https://doi.org/10.3390/v10070339>.